NexgenRx Inc.
NEGXF
$0.33
$0.0622.04%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 13.00M | 12.52M | 11.92M | 11.75M | 11.63M |
| Total Other Revenue | 258.40K | 257.90K | 689.50K | 494.10K | 390.00K |
| Total Revenue | 13.26M | 12.78M | 12.61M | 12.25M | 12.03M |
| Cost of Revenue | 2.03M | 2.09M | 2.31M | 2.42M | 2.45M |
| Gross Profit | 11.22M | 10.69M | 10.30M | 9.83M | 9.58M |
| SG&A Expenses | 8.29M | 8.22M | 8.00M | 7.84M | 7.77M |
| Depreciation & Amortization | 822.90K | 874.60K | 905.30K | 904.90K | 907.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.14M | 11.18M | 11.21M | 11.16M | 11.12M |
| Operating Income | 2.11M | 1.60M | 1.40M | 1.08M | 900.40K |
| Income Before Tax | 1.90M | 1.38M | 1.33M | 1.01M | 774.40K |
| Income Tax Expenses | 462.90K | 463.40K | 294.40K | 294.20K | 294.00K |
| Earnings from Continuing Operations | 1.44 | 0.92 | 1.03 | 0.71 | 0.48 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.44M | 921.30K | 1.03M | 712.50K | 480.30K |
| EBIT | 2.11M | 1.60M | 1.40M | 1.08M | 900.40K |
| EBITDA | 2.65M | 2.32M | 2.12M | 1.80M | 1.62M |
| EPS Basic | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 |
| Normalized Basic EPS | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 |
| EPS Diluted | 0.02 | 0.01 | 0.01 | 0.01 | 0.00 |
| Normalized Diluted EPS | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 |
| Average Basic Shares Outstanding | 284.47M | 284.47M | 283.82M | 283.78M | 283.59M |
| Average Diluted Shares Outstanding | 309.34M | 309.01M | 308.35M | 295.18M | 295.18M |
| Dividend Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Payout Ratio | 65.15% | 101.56% | 88.31% | 91.62% | 136.41% |